DDInter1085 DDInter1676
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lomitapide {u} (Compound) resembles {v} (Compound) Antrafenine
Lomitapide {u} (Compound) binds {v} (Gene) CYP3A4
Lomitapide {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Lomitapide {u} (Compound) causes {v} (Side Effect) Xanthoma
Lomitapide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Terbinafine
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Lomitapide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fexofenadine
Lomitapide (Compound) resembles Antrafenine (Compound)
Lomitapide (Compound) binds CYP3A4 (Gene)
Lomitapide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Lomitapide (Compound) causes Xanthoma (Side Effect)
Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lomitapide may lead to a major life threatening interaction when taken with Terbinafine
Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Lomitapide (Compound) resembles Fexofenadine (Compound) and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine